Bioethicist: 'Immunity Passports' Could Do More Harm Than Good : Coronavirus Live Updates The so-called passports have been floated as a way to get people who've recovered from COVID-19 back to work safely. But a Harvard professor says creating an "immunodeprived" status is unethical.
NPR logo

Bioethicist: 'Immunity Passports' Could Do More Harm Than Good

  • Download
  • <iframe src="https://www.npr.org/player/embed/865048097/865685812" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript
Bioethicist: 'Immunity Passports' Could Do More Harm Than Good

Bioethicist: 'Immunity Passports' Could Do More Harm Than Good

  • Download
  • <iframe src="https://www.npr.org/player/embed/865048097/865685812" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

AILSA CHANG, HOST:

Passports have been proposed as one way to get economies fired up again. These passports would rely on an antibody test - the theory being, if you have antibodies to the coronavirus you might be immune, and therefore you could be certified to work and circulate in society without posing a risk to yourself or to others. At least that's the idea, but this idea has a lot of flaws, according to bioethicist Natalie Kofler. She wrote about it in the journal Nature and joins us now. Welcome.

NATALIE KOFLER: Hi. Thanks for having me.

CHANG: Well, thanks for being here. First of all, who is interested in using these so-called immunity passports? Are we talking about governments, private companies, both?

KOFLER: Both, at this point. We've heard about certain governments that are exploring immunity passports as a potential policy to help reopen economies, governments including the U.K., the United States, as well as - Chile has actually already begun to sort of roll out a version of an immunity passport. Private companies are also interested particularly in partnering with certain app developers to create applications that would allow for people on their phones to validate and show their immunity status, in which case that could allow private companies like certain hotels and even sporting events to control who can enter their premises.

CHANG: OK. Well, let's talk about a few of the concerns that you raise in your article. First, there's this whole issue of immunity itself. I'm curious. Does having antibodies to COVID-19 mean you are actually immune to another infection by the virus?

KOFLER: So having antibodies to COVID-19 means that you have survived the virus, right?

CHANG: Right.

KOFLER: You've been infected and recovered. Likely, this gives some immunity to future infection. However, scientists still don't know how that immunity might work, meaning we don't know if everybody who has survived has a robust-enough immune response to be able to prevent future infection. We also don't know if immunity is possible from COVID-19 and how long it might last. If it's anything like the coronavirus that causes the common cold, immunity might last for only as little as, you know, four to six months. If it's like other coronaviruses, it could last longer, like the SARS virus could give you immunity maybe for one to two years.

CHANG: Right. What about the tests that even test for antibodies? I mean, do we even have enough of those tests? And are they reliable enough to support a whole system of immunity passports?

KOFLER: So one concern of ours is that there's currently real issues on - of the reliability of available tests for antibodies. There are some available that do have high enough sensitivity and specificity to be able to use as a measure for antibodies within people trying to determine their potential immune status. The problem there, though, is again a numbers issue. So there's only very few manufacturers of highly reliable tests. Roche is one of them out of Switzerland, for example. And right now, for example, they're guaranteeing, you know, several million tests a month to be produced, but that's going to be nowhere near enough to be able to validate entire, you know, populations...

CHANG: Yeah.

KOFLER: ...Of nations for their immune status.

CHANG: Well, another issue that you raised is this whole idea of equity, that the poor will simply not have as much access to these immunity passports. Explain what you mean by that.

KOFLER: Yeah, so we're really concerned about - knowing that immunity assessment through these antibody tests is going to be dependent on how many tests are available and knowing that those tests are going to be a scarce resource, those that are already marginalized by society - the poor, minority groups - they end up being often last in line for access to these precious resources.

CHANG: Right.

KOFLER: And so we have a lot of concern about who would actually be able to have their immunity status validated. You could have people that just aren't able to access society because they can't even be able to certify their immune status.

CHANG: Well, then, you know, given that there are several concerns with immunity passports, they may not be the answer - what is then?

KOFLER: So I really think attention needs to be given right now to really developing a vaccine that is effective but also that is going to be universally available. And I also do support maybe thinking about ways that we can protect particularly vulnerable locations and spaces. So it may be that, for example, to enter certain nursing homes or long-care facilities or to enter certain penitentiaries where there's high density people who are going to be at higher risk of COVID-19 that we might have health check status there, right?

We may want to check for, you know, presence of virus in people who are entering and exiting but not on the individual level, where everybody is going to either have, you know, an immuno-privileged sort of status or immuno-deprived status to be able to depend on where and what they can go do. I think that that could create a lot more harm than it does good.

CHANG: Bioethicist Natalie Kofler is also an adviser for the Scientific Citizenship Initiative at Harvard Medical School. This was so interesting. Thank you very much.

KOFLER: Thank you for having me. It was my pleasure.

Copyright © 2020 NPR. All rights reserved. Visit our website terms of use and permissions pages at www.npr.org for further information.

NPR transcripts are created on a rush deadline by Verb8tm, Inc., an NPR contractor, and produced using a proprietary transcription process developed with NPR. This text may not be in its final form and may be updated or revised in the future. Accuracy and availability may vary. The authoritative record of NPR’s programming is the audio record.